Výsledky vyhledávání - "Melissa Kirker"

Patient-reported symptom burden and treatment satisfaction in patients with metastatic urothelial cancer (mUC) in France, Germany, Italy, Spain, and the UK (Eu5)

Autor: Jane Chang, Nuno Costa, Mairead Kearney, Caspian Kluth, Callum Bleasdale, Rachel Montgomery, Melissa Kirker, Mia Unsworth, Neil Milloy, Maria Lapuente

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0310017d9ba8ee4c72bb90d2f7324cec
https://doi.org/10.26226/m.631864567e215f5e7f3852b3

Zobrazit plný text záznamu

Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II)

Autor: Petros Grivas, Pedro C. Barata, Helen Moon, Thomas E. Hutson, Shilpa Gupta, Cora N. Sternberg, Vaidehi Dave, Chad Downey, Alicia C. Shillington, Geeta Devgan, Melissa Kirker, Sheena Thakkar, Howard M. Katzenstein, Abhijeet Bhanegaonkar, Frank Liu, Jason Brown, Guru P. Sonpavde

Publikováno v: Journal of Clinical Oncology. 41:465-465

465 Background: The JAVELIN Bladder 100 clinical trial demonstrated a significant overall survival and progression-free survival benefit with avelumab 1LM + best supportive care (BSC) vs BSC alone for la/mUC not progressing on platinum-based chemothe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45eb064bdbcf035c7c6ed0b282dd6d35
https://doi.org/10.1200/jco.2023.41.6_suppl.465

Zobrazit plný text záznamu

Assessment of treatment patterns and real-world outcomes following changes in the treatment paradigm for locally advanced/metastatic urothelial carcinoma (la/mUC) in the US

Autor: Melissa Kirker, Anup Abraham, Anna Vlahiotis, Abhijeet Bhanegaonkar, Darrin Benjumea, Chai Kim, Haiyan Sun, Mairead Kearney, Sanjana Chandrasekar, Benjamin Li, Sheena Thakkar, Helen H Moon

Publikováno v: Journal of Clinical Oncology. 41:468-468

468 Background: The standard-of-care first-line (1L) treatment for la/mUC is platinum-based chemotherapy (PBC) followed by avelumab 1L maintenance (1LM) in those who have not progressed following 1L PBC. This study aims to understand treatment patter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0d9e063ae13f0134cd2f14e4e612a006
https://doi.org/10.1200/jco.2023.41.6_suppl.468

Zobrazit plný text záznamu

Criteria used to determine platinum eligibility and first-line (1L) treatment (tx) patterns among platinum-eligible (PE) and -ineligible (PI) patients (pts) with metastatic urothelial cancer (mUC) in France, Germany, Spain, Italy, and the United Kingdom (Eu5)

Autor: Neil Milloy, Melissa Kirker, Mia Berry, Michael Kostikas, Rachel Montgomery, Mairead Kearney, Nuno Matos Costa, Jane Chang

Publikováno v: Journal of Clinical Oncology. 40:457-457

457 Background: European Society for Medical Oncology (ESMO) guidelines recommend tx for mUC based on cisplatin and platinum eligibility. To date, most real-world analyses have not included physician-confirmed eligibility status. This study collected

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ae2d2965b35e255962d11d653aae06c
https://doi.org/10.1200/jco.2022.40.6_suppl.457

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání